The Food and Drug Administration (FDA) recently approved a new nonhormonal medication to treat the hot flashes and night sweats often experienced with menopause.

Veozah, or fezolinetant, made by Astellas Pharma, is the first approved neurokinin 3 (NK3) agonist. It blocks receptors in the brain that play a role in the regulation of body temperature.

Women at higher risk of stroke, heart attacks or some kinds of cancer are sometimes advised against using hormone replacement therapies because they increase the risk of blood clots and cancers. Veozah is an alternative to traditional hormone replacement therapies.

In clinical trials that included more than 3,000 women in the US and Canada, Veozah reduced the number of hot flashes women experienced each week significantly more than a placebo. The studies followed women who took the drug for a year.

Read the full article here.